Population Pharmacokinetics and Exposure–Response Analysis of Tremelimumab 300 mg Single Dose Combined with Durvalumab 1500 mg Q4W (STRIDE) in Patients with Unresectable Hepatocellular Carcinoma

银耳霉素 杜瓦卢马布 医学 人口 肿瘤科 内科学 药代动力学 肝细胞癌 癌症 环境卫生 免疫疗法 无容量 易普利姆玛
作者
KyoungSoo Lim,Aburough Abegesah,Chunling Fan,Zhijian He,Xuyang Song,Cecil Chen,Alejandra Negro,M. Makowsky,Charu Gupta,Song Ren,Alex Phipps,Megan Gibbs,Diansong Zhou
出处
期刊:The Journal of Clinical Pharmacology [Wiley]
卷期号:63 (11): 1221-1231 被引量:1
标识
DOI:10.1002/jcph.2288
摘要

A novel single-dose regimen of 300 mg tremelimumab in combination with durvalumab (STRIDE) has demonstrated a favorable benefit-risk profile in the phase 1/2 Study 22 trial (in patients with unresectable hepatocellular carcinoma, uHCC) and in the phase 3 HIMALAYA study. The current analysis evaluated the population pharmacokinetics (PopPK) of tremelimumab and durvalumab, and the exposure-response (ER) relationship for efficacy and safety of STRIDE in patients with uHCC. Previous PopPK models for tremelimumab and durvalumab were updated using data from previous studies in various cancers combined with data from Study 22 and HIMALAYA. Typical population mean parameters and associated inter- and intra-individual variability were assessed, as was the influence of covariates. Individual exposure metrics were derived from the individual empirical Bayes estimates as drivers for ER analysis related to efficacy and safety from HIMALAYA. The observed pharmacokinetics of tremelimumab in uHCC were well described by a 2-compartment model with both linear and time-dependent clearance. All identified covariates changed tremelimumab PK parameters by <25%, and thus had minimal clinical relevance; similar results were obtained from durvalumab PopPK analysis. None of tremelimumab or durvalumab exposure metrics were significantly associated with overall survival (OS), progression-free survival (PFS), or adverse events. Baseline aspartate aminotransferase and neutrophil-to-lymphocyte ratio (NLR) were associated with OS (P < .001) by the Cox proportional hazards model. No covariate was identified as a significant factor for PFS. No dose adjustment for tremelimumab or durvalumab is needed based on PopPK covariate analyses or ER analyses. Our findings support the novel STRIDE dosing regimen in patients with uHCC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Mm林完成签到,获得积分10
1秒前
我就是我完成签到,获得积分10
1秒前
盈滢完成签到 ,获得积分10
1秒前
Jay_Gavin应助白白采纳,获得10
2秒前
zy发布了新的文献求助10
3秒前
Liang发布了新的文献求助10
3秒前
美丽的楼房完成签到 ,获得积分10
5秒前
5秒前
大观天下完成签到,获得积分10
6秒前
端庄的冬天完成签到,获得积分10
6秒前
所所应助yizhe采纳,获得10
6秒前
高大的静曼完成签到,获得积分10
7秒前
JK完成签到,获得积分10
8秒前
景行行止完成签到,获得积分10
8秒前
草原狼完成签到,获得积分10
8秒前
8秒前
gexiaoyang完成签到 ,获得积分10
9秒前
量子星尘发布了新的文献求助10
10秒前
小二郎应助自信的孱采纳,获得10
10秒前
小马甲应助小王采纳,获得10
11秒前
伶俐的秋白完成签到,获得积分10
11秒前
11秒前
思源应助维生素采纳,获得10
12秒前
12秒前
完美梨愁发布了新的文献求助10
15秒前
15秒前
16秒前
英俊的铭应助白兰鸽采纳,获得10
18秒前
布洛小芬完成签到 ,获得积分20
19秒前
whatever应助shark采纳,获得20
19秒前
默默雪旋完成签到 ,获得积分10
19秒前
牧紫菱完成签到,获得积分10
20秒前
21秒前
22秒前
小王发布了新的文献求助10
22秒前
22秒前
Eric完成签到,获得积分10
23秒前
开朗的山彤完成签到,获得积分10
23秒前
维生素完成签到,获得积分10
23秒前
时林完成签到,获得积分10
23秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038388
求助须知:如何正确求助?哪些是违规求助? 3576106
关于积分的说明 11374447
捐赠科研通 3305798
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029